Nature Communications (Oct 2024)

Structure elucidation of a human melanocortin-4 receptor specific orthosteric nanobody agonist

  • Thomas Fontaine,
  • Andreas Busch,
  • Toon Laeremans,
  • Stéphane De Cesco,
  • Yi-Lynn Liang,
  • Veli-Pekka Jaakola,
  • Zara Sands,
  • Sarah Triest,
  • Simonas Masiulis,
  • Lies Dekeyzer,
  • Noor Samyn,
  • Nicolas Loeys,
  • Lisa Perneel,
  • Melanie Debaere,
  • Murielle Martini,
  • Charlotte Vantieghem,
  • Richa Virmani,
  • Kamila Skieterska,
  • Stephanie Staelens,
  • Rosa Barroco,
  • Maarten Van Roy,
  • Christel Menet

DOI
https://doi.org/10.1038/s41467-024-50827-7
Journal volume & issue
Vol. 15, no. 1
pp. 1 – 14

Abstract

Read online

Abstract The melanocortin receptor 4 (MC4R) belongs to the melanocortin receptor family of G-protein coupled receptors and is a key switch in the leptin-melanocortin molecular axis that controls hunger and satiety. Brain-produced hormones such as α-melanocyte-stimulating hormone (agonist) and agouti-related peptide (inverse agonist) regulate the molecular communication of the MC4R axis but are promiscuous for melanocortin receptor subtypes and induce a wide array of biological effects. Here, we use a chimeric construct of conformation-selective, nanobody-based binding domain (a ConfoBody Cb80) and active state-stabilized MC4R-β2AR hybrid for efficient de novo discovery of a sequence diverse panel of MC4R-specific, potent and full agonistic nanobodies. We solve the active state MC4R structure in complex with the full agonistic nanobody pN162 at 3.4 Å resolution. The structure shows a distinct interaction with pN162 binding deeply in the orthosteric pocket. MC4R peptide agonists, such as the marketed setmelanotide, lack receptor selectivity and show off-target effects. In contrast, the agonistic nanobody is highly specific and hence can be a more suitable agent for anti-obesity therapeutic intervention via MC4R.